Abnormal circadian rhythm of urinary sodium excretion correlates closely with hypertension and target organ damage in Chinese patients with CKD

Jun Zhang1#, Jialing Rao1#, Man Liu2, Wenying Zhou3, Yuanqing Li1, Jianhao Wu1, Hui Peng1*, Tanqi Lou1

1. Division of Nephrology, Department of medicine, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China.
2. Division of Gastroenterology and Hepatology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
3. Department of Laboratory medicine, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China.

# These authors contributed equally to this work.

* Corresponding author: Hui Peng, PhD, Division of Nephrology, Department of Medicine, Third Affiliated Hospital of Sun Yat -Sen University, 600 Tianhe Road, Guangzhou, Guangdong 510630, China. E-mail: pengh@mail.sysu.edu.cn.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Received: 2019.12.09; Accepted: 2020.02.03; Published: 2020.02.24

Abstract

Whether the abnormal circadian rhythm of urinary sodium excretion is associated with hypertension in chronic kidney disease (CKD) is poorly understood. In this study, we assessed the relationship between the circadian rhythm of urinary sodium excretion and hypertension. Urinary samples were collected during both the day (07:00 to 22:00) and night (22:00 to 07:00) to estimate night/day urinary sodium excretion ratios. Blood pressure (BP) and clinical data were also measured. A total of 1,099 Chinese CKD patients were recruited, 308 patients were excluded, and 791 patients were final enrolled in this study. Among them, 291 patients were normotensive and 500 were hypertensive CKD patients. A 1:1 propensity score matching (PSM) analysis was performed with age and estimated glomerular filtration rate (eGFR) matched between 190 normotensive and hypertensive patients. In the full cohort and PSM cohort, multivariate regression analysis showed that the night/day urinary sodium excretion ratio was an independent risk factor for clinical hypertension, whereas 24 h urinary sodium excretion, diurnal and nocturnal urinary sodium excretion were not. When the night/day urinary sodium excretion ratios were further divided into tertiles (tertile 1 < 0.47, tertile 2, 0.47–0.84 and tertile 3 > 0.84), multivariate analysis showed that tertile 3 was independently associated with hypertension in the full and PSM cohorts. In addition, tertile 3 was also independently associated with eGFR ≤ 60 mL/min/1.73 m² and left ventricular hypertrophy. These data suggested that an abnormal circadian rhythm of urinary sodium excretion was independently associated with hypertension and target-organ damage. Individualized salt intake and therapeutic strategies should be used to normalize the natriuretic dipping profile in CKD patients.

Key words: circadian rhythm, urinary sodium excretion, hypertension, target-organ damage.

Introduction

Chronic kidney disease (CKD) is a worldwide public health problem, with high economic costs and poor outcomes. Hypertension is the most frequent complication of CKD, and is considered both a cause and a consequence of it [1]. Hypertension is also a risk factor for the progression of kidney disease and cardiovascular (CV)-associated mortality [2]. A large proportion of patients with CKD have a “salt-sensitive” blood pressure (BP) phenotype because their renal sodium excretory capacity is reduced [3]. Although some studies have shown a positive relationship in the CKD population between BP and 24 h urinary sodium excretion, which is considered the gold standard measurement relating salt intake and BP [4, 5], whether high dietary sodium affects the initiation or progression of CKD is still unclear. Some [6, 7], but not all [8-11] studies of patients with CKD have shown that high dietary...

http://www.medsci.org
sodium intake may increase the risk of CKD progression and reduce long-term survival. However, there have been several publications reporting negative results [12, 13] in the general population or in young people [14] regarding the association between 24 h urinary sodium excretion and hypertension.

Thus, there is still no firm data showing that 24 h urinary sodium excretion is associated with hypertension, especially with target-organ damage (TOD), CKD progression and long-term survival. A previous study measured urinary sodium excretion separately during the day and night and found that nocturnal BP and BP dipping were closely associated with the daytime urinary sodium and day/night urinary sodium excretion ratio in African subjects. In this study, the authors divided the day/night urinary sodium excretion into tertiles and found a similar level of 24 h urinary sodium excretion but different BP among the tertiles in their population [15]. Therefore, more analysis employing stratification will be required to investigate these relationships.

In the CKD population, renal function deteriorates causing a decline in diurnal urinary sodium excretion, and impaired diurnal natriuresis increases pressure natriuresis, nocturnal BP, and nocturnal urinary sodium excretion to compensate for the diminished diurnal natriuresis [16, 17]. Consequently, the circadian rhythm in sodium excretion may change in these patients. Because most studies have not measured urinary sodium excretion separately during the day and night in the CKD population, they also have not analyzed the association between circadian changes in sodium excretion and BP or TOD. Therefore, we investigated the relationship between diurnal, nocturnal and 24 h urinary sodium excretion ratio, BP and TOD (in this study, left ventricular hypertrophy, impaired renal function and abnormal carotid intima-media thickness) in a Chinese CKD population.

**Methods**

**Study population**

This study was approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. Written informed consent was obtained from all the patients before their enrollment. We recruited 1,099 consecutive patients from the Third Affiliated Hospital of Sun Yat-sen University between July 2010 and December 2019. The inclusion criteria were: aged 14–75 years and diagnosed with CKD [18]. The exclusion criteria were: other causes resulting in secondary hypertension such as renovascular hypertension, Cushing’s syndrome or aldosteronism; sustained BP higher than 200/120 mmHg; took an anti-hypertensive medication (before BP data and urinary sodium were collected, short-acting amlodipine was used according to the patient’s condition) or diuretic drug in the previous month; treatment with corticosteroids or hormones; acute changes in the estimated glomerular filtration rate (eGFR) > 30% in the previous 3 months; maintenance dialysis; kidney transplantation; history of drug or alcohol abuse; employment involving night work or shiftwork; acquired immunodeficiency syndrome; inability to communicate or comply with all the study requirements; pregnancy; and refusal to provide informed consent.

A total of 308 patients were excluded for the following reasons (Fig. 1). In total, 791 CKD patients were enrolled in the study. The causes of CKD were chronic glomerulonephritis in 481 patients (60.81%), diabetic nephropathy in 122 patients (15.4%), interstitial nephritis in 44 patients (12.52%), obstructive nephropathy in 51 patients (3.53%), and other causes in 93 patients (7.54%; Fig. 1). Using the propensity score matching (PSM) extension program, 380 CKD patients were assigned to the hypertensive group or the normotensive group in 1:1 PSM (Fig. 1).

**Clinical data collection**

BP measurements were made in a quiet environment using a mercury sphygmomanometer, with the patient in a sitting position after 5 min of rest. The details have been reported previously [19, 20]. Data were collected at the initial study visit, and included demographic information, laboratory data (hemoglobin, albumin, calcium, phosphorus, intact parathyroid hormone [iPTH], fasting blood glucose, serum cholesterol, triglycerides, high-density lipoprotein-cholesterol [HDL_C], low-density lipoprotein-cholesterol [LDL_C], homocysteine, uric acid, serum creatinine [Scr], and blood urea nitrogen [BUN]), and any current treatment. The laboratory data were measured with a 7180 Biochemical Automatic Analyzer (Hitachi, Tokyo, Japan). We collected urine samples from 07:00 to 22:00 (diurnal) when the patients were awake and between 22:00 to 07:00 (nocturnal) when the patients were in bed. The patients were asked to void their bladders at 07:00 and 22:00 to ensure valid results. The diurnal and nocturnal urinary sodium levels, the 24 h urinary protein levels, and 24 h urinary sodium excretion were measured. Proteinuria was assessed by immune turbidimetry. The concentration of sodium in the urine was measured with flame spectrophotometry.
Ultrasonographic assessment

The cardiac structure and carotid intima-media thickness (cIMT) were assessed as previously described [21]. The left ventricular mass index (LVMI) was obtained by calculating the left ventricular mass to height\(^2.7\) [22], and patients with LVMI of 49 g/m\(^{2.7}\) (man) or 45 g/m\(^{2.7}\) (woman) were diagnosed with left ventricular hypertrophy (LVH) [23]. The cIMT was assessed by two trained investigators before the commencement of the study.

Definitions

- Systolic blood pressure (SBP) < 140 mmHg and diastolic blood pressure (DBP) < 90 mmHg were defined as “normotension,” and other values were defined as ‘hypertension’. CKD was defined in accordance with the KDIGO 2012 Clinical Practice Guidelines [18]. eGFR levels were calculated with the 2009 CKD-EPI creatinine equation [24]. Diabetes mellitus (DM) was defined as the need for antidiabetic drugs or meeting the diagnostic criteria according to the American Diabetes Association’s Standards of Medical Care in Diabetes [25]. TOD was defined as follows: first, left ventricular hypertrophy (LVH) was diagnosed as LVMI > 49 g/m\(^2\) (male) or > 45 g/m\(^2\) (female); second, with respect to large-vessel disease, cIMT > 1 mm was regarded as abnormal [26]; third, impaired renal function was defined as eGFR < 60 mL/min/1.73 m\(^2\) [18]. The circadian rhythm of urinary sodium excretion was determined by the night/day urinary sodium excretion ratio.

Statistical analyses

Descriptive statistics are presented as means ± standard deviations for continuous variables and as medians and interquartile ranges for nonparametric variables. Frequencies and percentages were used for categorical variables. The differences between qualitative variables were assessed with the \(\chi^2\) test or Fisher’s exact test. Comparisons of continuous variables between groups were evaluated with Student’s \(t\)-test or ANOVA; discontinuous variables were evaluated with nonparametric tests (the Kruskal-Wallis \(H\) test for several independent
samples and the Mann–Whitney U test for two independent samples. To reduce the selection bias conferred by potential confounding factors, a PSM analysis was performed with age and eGFR matched between the normotensive and hypertensive groups. The logit of the propensity score was nearest-neighbor matched in a 1:1 manner, with a caliper of 0.02 with no replacements. Multivariable regression analyses were used to model the relationships between hypertension and urinary sodium excretion and the night/day urinary sodium excretion ratio. All values were two-tailed, and a P < 0.05 was considered to indicate statistical significance. All data were analyzed with IBM SPSS Statistics, version 25.0 for Windows (IBM, Armonk, NY, USA).

Results

Demographic and clinical characteristics of the study population

The mean age of the full cohort was 44.5 years and 59.5% of the patients were male. The prevalence of current smokers and alcohol abusers in the full cohort was 19.7% and 10.6%, respectively, and 17.4% patients were diagnosed with DM (Table 1). Among the full cohort, patients with hypertension were older, with a higher prevalence of smokers, DM, LVH, eGFR < 60 mL/min/1.73 m2, and abnormal cIMT than the normotensive patients, and higher mean BMI, fasting glucose, serum phosphate, triglyceride, proteinuria, serum Scr, uric acid, serum cystatin C, nighttime urinary sodium excretion, night/day urinary sodium excretion ratio, LVMI, and cIMT. The hypertensive patients also had lower hemoglobin, total calcium, eGFR, cholesterol, LDL_C, HDL_C, and diurnal urinary sodium excretion. (P < 0.05; Table 1). There was no difference in 24 h urinary sodium excretion between the two groups.

In the PSM analysis that matched age and eGFR, 190 normotensive patients were pair-matched with 190 hypertensive patients in the PSM cohort. We found no differences in the demographic or clinical characteristics of the two groups, in terms of their age, sex, current smoking status, alcohol intake, hemoglobin, albumin, serum Scr, eGFR, cholesterol, LDL_C, HDL_C, uric acid, 24 h urinary sodium excretion, or diurnal urinary sodium excretion (P > 0.05; Table 1). However, the hypertensive group included greater proportions of patients with DM, LVH, and abnormal cIMT, higher levels of fasting glucose, triglyceride, proteinuria, LVMI, cIMT, and nocturnal urinary sodium excretion, and higher night/day urinary sodium excretion ratios than the normotensive patients (P < 0.05; Table 1).

Characteristics of urinary sodium excretion in CKD patients with different BP and eGFR

To further understand the relationships between BP, eGFR, and urinary sodium excretion, we divided the whole group into the normotensive and eGFR ≥ 60 mL/min/1.73 m2 group (group 1, n = 245), the hypertensive and eGFR ≥ 60 mL/min/1.73 m2 group (group 2, n = 207), the normotensive and eGFR < 60 mL/min/1.73 m2 group (group 3, n = 54), and the hypertensive and eGFR < 60 mL/min/1.73 m2 group (group 4, n = 285). The 24 h urinary sodium excretion was significantly lower in group 4 (121.26 ± 66.61 mmol) than in group 1 (137.81 ± 85.45 mmol) and group 2 (141.04 ± 66.53 mmol). Group 3 (117.21 ± 55.40 mmol) also had significantly lower 24 h urinary sodium excretion than group 2. There were no differences in 24 h urinary sodium excretion between the hypertensive patients and the normotensive patients in the eGFR < 60 mL/min/1.73 m2 group or the eGFR ≥ 60 mL/min/1.73 m2 group. Diurnal urinary sodium excretion was significantly lower in group 4 (74.07 ± 40.35 mmol) and group 3 (68.55 ± 47.58 mmol) than in group 1 (98.49 ± 63.99 mmol) and group 2 (90.43 ± 53.70 mmol). There was no difference in diurnal urinary sodium excretion between the hypertensive patients and the normotensive patients in the eGFR < 60 mL/min/1.73 m2 group or the eGFR ≥ 60 mL/min/1.73 m2 group. Nocturnal urinary sodium excretion was significantly higher in group 2 (53.47 ± 29.71 mmol), group 3 (50.35 ± 27.14 mmol) and group 4 (54.73 ± 31.29 mmol) when compared to group 1 (47.58 ± 29.71 mmol). In the hypertensive group, there was no difference in nocturnal urinary sodium excretion between patients with different eGFR levels, and nocturnal urinary sodium excretion did not differ between the hypertensive and normotensive patients when eGFR < 60 mL/min/1.73 m2. The night/day urinary sodium excretion ratio was significantly higher in group 2 (0.58, 0.36–0.88), group 3 (0.65, 0.53–0.86), and group 4 (0.85, 0.55–1.16) than in group 1 (0.41, 0.27–0.61), and it was also significantly higher in group 4 than in the other groups. It did not differ between groups 2 and 3 (Figure 2).
Table 1. Differences in demographic and clinical characteristics of ambulatory normotensive patients and hypertensive patients.

|                     | Full cohort (N=791) | PSM cohort* (N=380) |
|---------------------|---------------------|---------------------|
|                     | Total               | Normotension (N=291) | Hypertension (N=500) | P     |
|                     | (N=791)             | (N=291)             | (N=500)              |       |
| Age (years)         | 44.5±5.77           | 38.6±5.49           | 49.1±6.24            | <0.001|
| Male:female ratio   | 47.1±32             | 163.1±128          | 308.1±192            | 0.133 |
| Current smoker, n (%) | 156 (19.7)         | 45 (15.5)           | 111 (22.2)            | 0.026 |
| Alcohol intake, n (%) | 84 (10.6)          | 20 (6.9)            | 60 (12.0)             | 0.119 |
| Diabetes mellitus, n (%) | 138 (17.4)        | 23 (7.9)            | 115 (23.0)            | <0.001|
| BMI (kg/m²)         | 23.6±4.69           | 23.3±4.33           | 23.6±3.53             | <0.001|
| Total calcium (mmol/l) | 2.1±0.24         | 2.1±0.25            | 2.1±0.23              | 0.03 |
| Serum phosphate (mmol/l) | 1.4±0.46         | 1.9±0.32            | 1.4±0.51              | <0.001|
| Serum sodium (mmol/l) | 139.8±9.21        | 140.2±9.24          | 139.7±11.31           | 0.27  |
| Hemoglobin (g/l)    | 112.2±29.64         | 123.4±24.16         | 105.8±30.99           | 0.001 |
| Albumin (g/l)       | 34.3±8.17           | 34.2±8.13           | 34.4±9.57             | 0.742 |
| Fasting glucose (mmol/L) | 5.1±1.51         | 4.8±1.11            | 5.3±1.67              | <0.001|
| Cholesterol (mmol/L) | 5.5±2.48           | 5.8±2.64            | 5.4±2.36              | 0.012 |
| Triglycerides (mmol/L) | 1.9±1.68          | 1.7±1.36            | 2.0±1.83              | <0.001|
| HDL-C (mmol/L)      | 1.8±0.42            | 1.3±0.48            | 1.1±0.37              | <0.001|
| LDL-C (mmol/L)      | 80.2±10.66          | 80.2±10.66          | 78.3±10.93            | 0.001 |
| Albumin (g/d)       | 3.5±1.85            | 3.8±2.00            | 3.9±1.75              | <0.001|
| Uric acid (mmol/L)  | 483.5±152.10        | 430.4±146.24        | 513.5±148.31          | 0.254 |
| Serum creatinine (mg/l) | 2.4±1.75          | 3.1±1.30            | 3.0±1.75              | <0.001|
| Serum creatinine (mg/l) | 151.5±80           | 160±80              | 127.9±68              | <0.001|
| eGFR-MDRD (ml/min/1.73m²) | 52.7±44.00       | 81.8±43.49          | 36.2±26.74            | <0.001|
| eGFR <60 (ml/min/1.73m²) | 348 (44.0)        | 51 (17.5)           | 297 (59.4)            | <0.001|
| Proteinuria (g/d)   | 1.4±0.48            | 0.87(0.26-0.8)      | 1.87(0.7-1.42)        | <0.001|
| 24 h Urine excretion (mmol) | 135.8±72.25       | 139.5±77.06         | 133.7±67.63           | 0.27 |
| Diurnal Urine excretion (mmol) | 84.7±53.72        | 94.2±55.09          | 79.1±30.89            | <0.001|
| Nocturnal Urine excretion (mmol) | 51.1±34.22        | 45.9±32.53          | 54.8±32.53            | <0.001|
| Night/day Urine excretion ratio | 0.77±0.63       | 0.58±0.46           | 0.88±0.68             | <0.001|
| LVH (g/m²)          | 49.6±26.14          | 39.6±10.10          | 55.0±15.24            | <0.001|
| Abnormal cIMT, n (%) | 390 (49.3)         | 65 (22.3)           | 325 (65.0)            | <0.001|
| SBP (mmHg)          | 134.3±18.40         | 115.5±8.29          | 145.2±13.12           | <0.001|
| DBP (mmHg)          | 80.2±10.66          | 70.5±5.42           | 85.9±4.68             | <0.001|

PSM: propensity score matching; DBP: diastolic blood pressure; SBP: systolic blood pressure; DM: diabetes mellitus; eGFR: estimated glomerular filtration rate; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; iPTH: intact parathyroid hormone; cIMT: carotid intima-media thickness; LVMI: left ventricular mass index; LHV: left ventricular hypertrophy.
* PSM analysis was performed with age and eGFR matched between the normotensive and hypertensive groups.

P values are for the comparison between normotensive and hypertensive patients.

Table 2. Multivariate logistic regression analysis of the relationship between hypertension and urinary sodium excretion in patients with CKD.

| Variable                      | Full cohort (N=791) | PSM cohort (N=380) |
|-------------------------------|---------------------|---------------------|
|                              | Multivariate regression analysis OR (95% CI) | Multivariate regression analysis OR (95% CI) |
|                              | Model 1             | Model 2             | Model 1             | Model 2             |
| 24 h Urine excretion (per mmol) | 1.00 (0.997-1.003) | -                   | 0.999 (0.994-1.003) | -                   |
| Diurnal Urine sodium excretion (per mmol) | 0.996 (0.993-1.000)* | 1.00 (0.995-1.004) | 0.995 (0.989-1.000) | -                   |
| Nocturnal Urine excretion (per mmol) | 1.008 (1.001-1.016)* | 1.000 (1.003-1.008) | 1.000 (1.001-1.017)* | 1.003 (0.994-1.002) |
| Night / day Urine excretion ratio | 2.269 (1.383-3.721)** | 2.085 (1.147-3.790)** | 2.043 (1.258-3.317)** | 1.878 (1.105-3.192)** |

PSM: propensity score matching.
CI: confidence interval. Urinary sodium excretion with no significant associations in model 1 was not included in model 2.

Model 1: multivariate logistic regression analysis of the relationships between hypertension and 24 h urinary sodium excretion, diurnal urinary sodium excretion, nocturnal urinary sodium excretion and the day/night urinary sodium excretion ratio. Variables for the simple regression analysis of hypertension included age, sex (female = 0, male = 1), diabetes mellitus, current smoking status, alcohol intake, BMI, hemoglobin, LDL-C, calcium, phosphate, iPTH, 24 h proteinuria and eGFR (1 = eGFR ≥60 ml/min/1.73 m²; 2 = eGFR <60 ml/min/1.73 m²).

Model 2 variables: age, sex (female = 0, male = 1), diabetes mellitus, current smoking status and alcohol intake; variables included that were significantly associated with hypertension in model 1 were also included in the multiple regression analysis.

* PSM analysis was performed with age and eGFR matched between the normotensive and hypertensive groups. ‘P < 0.05, ‘P < 0.01.

http://www.medsci.org
Regression analysis of the relationships between hypertension and different kinds of urinary sodium excretion

In a multivariate regression analysis of the full cohort (Table 2, model 1), hypertension was independently associated with low diurnal urinary sodium excretion, high nocturnal urinary sodium excretion, and a high night/day urinary sodium excretion ratio, but not with 24 h urinary sodium excretion. In model 2, in which the factors significantly associated with urinary sodium in model 1 were included in a multivariate regression analysis, we found that only the night/day urinary sodium excretion ratio was independently associated with hypertension (Table 2).

To adjust the selection bias conferred by potential confounding factors, a PSM analysis was performed. In model 1, we found that high nocturnal urinary sodium excretion and a high night/day urinary sodium excretion ratio were associated with hypertension. The same analysis of the whole cohort found that only the night/day urinary sodium excretion ratio was independently associated with hypertension in model 2 (Table 2).

Baseline characteristics and the different tertiles of the night/day urinary sodium excretion ratio

To further analyze the effects of the night/day urinary sodium excretion ratio on hypertension and TOD in CKD patients, we divided them into three equally sized groups: tertile 1 (night/day urinary sodium excretion ratio < 0.47), tertile 2 (0.47–0.84), and tertile 3 (night/day urinary sodium excretion ratio > 0.84). Tertile 3 had a higher proportion with DM, LVH, and eGFR < 60 mL/min/1.73 m², was older, had higher serum phosphate, serum Scr, serum cystatin C, iPTH, nocturnal urinary sodium excretion, LVMi, SBP and DBP, and had lower hemoglobin, eGFR-MDRD and diurnal urinary sodium excretion than tertile 1 and tertile 2. Tertile 3 also had higher fasting glucose, uric acid, and cIMT, and lower cholesterol, HDL_C, LDL_C, and 24 h urinary sodium excretion than tertile 1 (Table 3). Tertile 2 had a higher prevalence of DM, hypertension, abnormal cIMT, and LVH, older age, higher serum phosphate, uric acid, serum cystatin C, Scr, nocturnal urinary sodium excretion, LVMi, and cIMT, and lower hemoglobin, LDL_C, HDL_C, diurnal urinary sodium excretion, 24 h urinary sodium excretion, and eGFR than tertile 1 (Table 3).
### Table 3. Baseline characteristics of patients with CKD stratified by tertiles of the night/day urinary sodium excretion ratio.

| Variable | T1 < 0.47 (n = 264) | T2 0.47–0.84 (n = 264) | T3 > 0.84 (n = 263) |
|----------|----------------------|------------------------|----------------------|
| Age (years) | 38.62±14.82 | 43.35±15.53* | 47.94±13.24** |
| Male: female ratio | 166:98 | 159:105 | 150:114 |
| Current smoker, n (%) | 53 (20.1) | 50 (18.9) | 52 (19.8) |
| Alcohol intake, n (%) | 9 (3.4) | 11 (4.2) | 8 (3.0) |
| Diabetes mellitus, n (%) | 27 (10.2) | 46 (17.4)† | 66 (25.1)∗∗ |
| BMI (kg/m²) | 22.25±3.61 | 22.84±3.37 | 23.36±3.65 |
| Total calcium (mmol/L) | 2.21±0.22 | 2.18±0.27 | 2.15±0.28 |
| Serum phosphate (mmol/L) | 1319±0.33 | 14±0.44** | 1.52±0.56*** |
| Serum albumin (g/L) | 40.24±3.39 | 40.20±8.99 | 40.31±3.37 |
| Hemoglobin (g/L) | 124.15±28.23 | 112.00±28.68* | 100.58±22.30** |
| Albumin (g/L) | 34.31±9.25 | 34.76±8.18 | 34.10±6.89 |
| Fasting glucose (mmol/L) | 1.93±1.02 | 1.67±1.02 | 1.57±1.05 |
| Cholesterol (mmol/L) | 5.96±2.67 | 5.47±2.48* | 5.29±2.21†† |
| Triglyceride (mmol/L) | 1.94±1.42 | 2.05±1.81 | 1.88±1.79 |
| HDL-C (mmol/L) | 1.25±0.45 | 1.16±0.43 | 1.14±0.40** |
| LDL-C (mmol/L) | 3.94±2.05 | 3.43±1.80** | 3.28±1.59** |
| Uric acid (mmol/L) | 451.68±137.72 | 493.60±148.65** | 505.21±164.30*** |
| Serum cystatin C (mg/L) | 1.74±1.29 | 2.59±1.86** | 3.16±1.75*** |
| Serum creatinine (μmol/L) | 97.90 | 156.00 | 332.30 |
| (μmol/L) (68.80-185.75) | (92.10-474.75) | | (122.87-688.25) ** |
| eGFR-MDRD (ml/min/1.73m²) | 74.61±45.69 | 48.27±40.69** | 35.33±34.42** |
| eGFR ≤ 60 (ml/min/1.73m²) | 61 (23.1) | 116 (43.9)** | 170 (64.6)** |
| Proteinuria (g/d) | 1.45 (0.38-3.63) | 1.45 (0.44-3.59) | 1.77 (0.69-4.16) |
| 24 h UNa excretion (mmol) | 24 h UNa excretion (mmol) | 24 h UNa excretion (mmol) |
| Diurnal UNa excretion (mmol) | 117.19±6.53 | 81.16±39.81** | 55.88±30.39** |
| Nocturnal UNa excretion (mmol) | 32.71±17.41 | 49.86±24.22** | 51.12±34.22** |
| Night/day UNa excretion ratio | 0.30±0.10 | 0.63±0.10** | 1.40±0.73** |
| LVMI (g/m²) | 44.24±14.61 | 49.10±14.42** | 55.28±17.28** |
| LVH, n (%) | 87 (32.9) | 126 (47.7)** | 174 (66.2)** |
| cIMT (mm) | 0.67±0.24 | 0.70±0.28 | 0.79±0.23** |
| Abnormal cIMT, n (%) | 36 (13.6) | 86 (32.7)** | 86 (32.7)** |
| Clinic-SBP (mmHg) | 128.10±18.93 | 134.16±16.50** | 140.73±17.61*** |
| Clinic-DP (mmHg) | 76.80±10.62 | 80.57±10.12 | 83.31±10.25** |
| Hypertension, n (%) | 117 (44.8) | 170 (63.0)** | 212 (81.9)** |

DBP: diastolic blood pressure; SBP: systolic blood pressure; DM: diabetes mellitus; eGFR: estimated glomerular filtration rate; BMI: body mass index; HDL-C: high-density lipoprotein–cholesterol; LDL-C: low-density lipoprotein–cholesterol; iPTH: intact parathyroid hormone; cIMT: carotid intima-media thickness; LVMI: left ventricular mass index; LVH: left ventricular hypertrophy. **P < 0.01, *P < 0.05, **P < 0.001.

### Table 4. Logistic regression analysis of the relationship between hypertension and different tertiles of the night/day urinary sodium excretion ratio in full and PSM cohorts of patients with CKD.

| Hypertension, n (%) | Univariate regression analysis | Multivariate regression analysis |
|---------------------|-------------------------------|----------------------------------|
| Full cohort (N=791) | Reference | Reference |
| T1, 117 (44.8) | 2.092 (1.479–2.092)∗∗ | 2.092 (1.479–2.092)∗∗ |
| T2, 170 (63.0) | 5.578 (3.742–8.315)∗∗ | 5.578 (3.742–8.313)∗∗ |
| T3, 212 (81.9) | 4.270 (2.168–8.420)∗∗ | 3.593 (1.867–7.332)∗∗ |

PSM: propensity score matching.

#### Discussion

In this study, we evaluated BP and TOD in relation to diurnal, nocturnal, and 24 h urinary sodium excretion and the night/day urinary sodium excretion ratio. The following findings have emerged. First, we demonstrated that there was no significant difference in the 24 h urinary sodium excretion rates between normotensive and hypertensive CKD patients. Second, in our cohort, patients with eGFR ≥ 60 mL/min/1.73 m² and the normotensive groups variables significantly associated with hypertension in the univariate regression analysis, tertile 2 and tertile 3 in the full cohort and PSM cohort were all independently related to hypertension (p < 0.05; Table 4).
had the lowest night/day urinary sodium excretion ratios. The hypertensive patients with eGFR < 60 mL/min/1.73 m² had the highest night/day urinary sodium excretion ratio of all the groups. Third, multivariate logistic regression analyses of the full cohort and the PSM cohort showed that high night/day urinary sodium ratios correlated closely with hypertension. Fourth, multivariate regression analysis showed that the tertile with the highest night/day urinary sodium excretion ratio (> 0.84) was independently associated with hypertension, lower eGFR and LVH.

### Table 5. Logistic regression analysis of the relationship between eGFR < 60 mL/min/1.73 m², LVH, abnormal cIMT and different tertiles of the night/day urinary sodium excretion ratio in patients with CKD.

| Variable | Univariate regression analysis | Multivariate regression analysis |
|----------|-------------------------------|--------------------------------|
|          | OR (95% CI)                   | OR (95% CI)                   |
| eGFR (1 = eGFR ≥ 60 mL/min/1.73 m²; 2 = eGFR < 60 mL/min/1.73 m²) | Reference | Reference |
| T1       | 2.607 (1.782 - 3.813)*        | 1.890 (0.982 - 3.640)         |
| T2       | 6.115 (4.144 - 9.023)**       | 2.675 (1.365 - 5.243)**       |
| LVH (1 = no LVH; 2 = LVH) | Reference | Reference |
| T1       | 1.859 (1.202 - 2.873)*        | 1.356 (0.735 - 2.479)         |
| T2       | 4.005 (2.568 - 6.244)**       | 2.050 (1.076 - 3.906)*        |
| cIMT (1 = cIMT≤1 mm; 2 = cIMT>1 mm) | Reference | Reference |
| T1       | 1.961 (1.014 - 3.794)*        | 1.344 (0.572 - 3.158)         |
| T2       | 3.081 (1.615 - 5.879)**       | 1.653 (0.696 - 3.922)         |

cIMT: carotid intima-media thickness; LVMI: left ventricular mass index; LVH: left ventricular hypertrophy.

Variables for the multivariate regression analysis of LVH and abnormal cIMT included age, sex, diabetes mellitus, current smoking status, alcohol intake, BMI, hemoglobin, LDL_C, total calcium, serum phosphate, iPTH, 24 h proteinuria, eGFR (1 = eGFR ≥ 60 mL/min/1.73 m²; 2 = eGFR < 60 mL/min/1.73 m²) and blood pressure (1=normotension, 2= hypertension). Variables for the multivariate regression analysis of eGFR < 60 mL/min/1.73 m² included age, sex, diabetes mellitus, current smoking status, alcohol intake, BMI, hemoglobin, LDL_C, total calcium, serum phosphate, iPTH, 24 h proteinuria and blood pressure (1=normotension, 2= hypertension).

We observed lower 24 h urinary sodium excretion in patients in the eGFR < 60 mL/min/1.73 m² group, which was also reported in a previous study [9]. This was perhaps attributable to a reduced dietary intake of salt related to poor appetite. In addition, we observed no positive relationship between BP and 24 h urinary sodium excretion, which is inconsistent with a previous CKD study [5]. Several factors may explain this discrepancy. First, the effects of confounding factors, such as age, genetics, environmental factors, different CKD stages, and comorbidities, may cause CKD patients to display different salt-sensitive BP changes. Second, the average of 24 h urinary sodium excretion was 139.51±77.06 mmol in normotensive patients and 133.71±67.63 mmol in hypertensive patients, which is a relatively lower level in our CKD cohort compared to the previous study [5]. Therefore, it was difficult to demonstrate a positive relationship between 24 h urinary sodium excretion and BP levels.

In this study, we observed that the night/day urinary sodium excretion ratio correlated with hypertension. The potential mechanism has been explained by Fukuda et al. in 2010[17]. A reduced renal sodium excretory capacity has been recognized in the salt-sensitive type of hypertension and in CKD patients, and when the salt intake is higher than appropriate, a defect in the diurnal sodium excretory capacity becomes evident, and urinary sodium excretion remains relatively low, resulting in elevated nocturnal BP to compensate for the diminished natriuresis during the daytime. This increases pressure natriuresis and more sodium is excreted during the night, so the normal circadian rhythm of urinary sodium excretion is disturbed [17]. If nocturnal pressure natriuresis compensates for the reduced sodium excretion from the kidneys during the day, high BP may continue during the night until sufficient excess sodium is excreted in the urine.

Kidney Disease Improving Global Outcomes (KDIGO) suggests a reduction to < 2 g/day sodium, corresponding to 5 g/day salt, for adult patients with CKD [18]. These recommendations are based on low level evidence from studies with marked heterogeneity [27]. The current recommendations make no distinction between CKD stage or comorbidities. Furthermore, the KDIGO does not account for salt sensitivity in their recommendations. Recommending the same salt cut-off value for the whole CKD population may not benefit all patients. The circadian rhythm of urinary sodium excretion may be a sensitive index for sodium excretory capacity and salt sensitivity, which could predict both high BP and TOD. The recommended total salt intake should be individualized, with the patient’s circadian rhythm of urinary sodium excretion taken into consideration. For example, in a CKD hypertensive patient with a normal circadian rhythm of urinary sodium excretion, salt intake may not be the reason for hypertension. Therefore, strictly limiting his/her salt intake may be of no benefit to his/her BP. Recently studies revealed an association between low urinary sodium excretion and worse prognosis [28, 29]. More studies are required to investigate the relationship between the circadian rhythm of urinary sodium excretion and BP.

This study had several advantages and limitations. To the best of our knowledge, this is the first study to explore the relationships between the circadian rhythm of urinary sodium excretion, hypertension, and TOD in a CKD population. Urinary sodium excretion was measured separately and...
provided more information regarding the significance of urinary sodium excretion during the day and night, especially night/day urinary sodium excretion ratio. The potential limitations of our study include that it was a real world observational cross-sectional study and therefore could not establish the cause-effect relationship between the circadian rhythm of urinary sodium excretion and BP. In the future, a follow-up study should investigate the relationships between the circadian rhythm of urinary sodium excretion and hypertension, TOD and the prognosis of CKD; This study did not allow us to determine the mechanism(s) by which a higher night/day sodium excretion ratio is associated with TOD; Although they do not compensate for a truly random design, the large number of subjects in our study and controlling for several potential confounders (age, GFR) with PSM and multivariate regression analyses improved the credibility of our results.

In conclusion, the results of this study clearly demonstrated that in patients with CKD, an abnormal circadian rhythm of urinary sodium excretion is closely related to hypertension and TOD. In CKD patients, the recommended salt intake should also take into account the individual’s circadian rhythm of urinary sodium excretion. We suggest that in addition to 24 h urinary sodium excretion, both diurnal and nocturnal urinary sodium excretion should be measured in these patients.

Acknowledgements
The authors would like to acknowledge all patients and their families for participating in this study.

Authors’ Contributions
JZ participated in the study design, performed literature review, and aided in manuscript preparation. JLR and ML performed the database setup and statistical analysis and participated in manuscript writing. WYZ performed laboratory data measurements. YQL and JHW were responsible for enrolling patients and data collection. PH and TQL participated in the study design and coordination. All of the authors have read and approved the final manuscript.

Funding
This work was financially supported by “the project of cultivating young teachers in Sun Yat-sen University” (No. 17kypy56).

Competing Interests
The authors have declared that no competing interest exists.

References
1. Horowitz B, Miskulin D, Zager P: Epidemiology of hypertension in CKD. Adv Chronic Kidney D 2015, 22(2):88-95.
2. Tomelli M, Weibe N, Culleton B, House A, RabbaI C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 2006, 17(7):2034-2047.
3. Kimura G: Kidney and circadian blood pressure rhythm. Hypertension 2008, 51(4):827-828.
4. Saran R, Padilla RL, Gillespie BW, Heung M, Hammel SL, Dereband VK, Pitt B, Levin NW, Zhu F, Abbas SR et al: A randomized crossover trial of dietary sodium restriction in stage 3-4 CKD. Clin J Am Soc Nephrol 2017, 12(3):399-407.
5. Koo HS, Kim YC, Ahn SY, Oh SW, Kim S, Chin HJ: Analysis of correlation between 24-hour urinary sodium and the degree of blood pressure control in patients with chronic kidney disease and non-chronic kidney disease. J Korean Med Sci 2014, 29:S117-S122.
6. Vegeter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P: Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012, 23(1):165-173.
7. He J, Mills KT, Appel LJ, Yang W, Chen J, Lee BT, Rosas SE, Porter A, Makos G, Weir MR et al: Urinary sodium and potassium excretion and CKD progression. J Am Soc Nephrol 2016, 27(4):1202-1212.
8. Fan L, Tighiouart H, LeveY AS, Beck GJ, Sarnak MJ: Urinary sodium excretion and kidney failure in nondiabetic chronic kidney disease. Kidney Int 2014, 86(3):583-588.
9. McQuarrie EP, Traypor JP, Taylor AH, Freed EM, Fox JC, Jardine AG, Mark PB: Association between urinary sodium, creatinine, albumin, and long-term survival in chronic kidney disease. Hypertension 2014, 64(1):111-117.
10. Norris KC, Greene T, Koppel J, Lea J, Lewis J, Lipkowitz M, Miller P, Richardson A, Rostand S, Wang XL et al: Baseline predictors of renal disease progression in the African American study of hypertension and kidney disease. J Am Soc Nephrol 2006, 17(10):2928-2936.
11. Kieneker LM, Bakker SJL, de Boer RA, Navis GJ, Gansevoort RT, Joosten MM: Low potassium excretion but not high sodium excretion is associated with increased risk of developing chronic kidney disease. Kidney Int 2016, 90(4):888-896.
12. Asfar B, Elsurer R, Kirkpartrur A, Kanbay M: Urinary sodium excretion and ambulatory blood pressure findings in patients with hypertension. J Clin Hypertens 2015, 17(3):200-206.
13. Moliterno P, Alvarez-Vaz R, Pecora M, Luzzardo L, Borgarello L, Olascoaga A, Marino C, Nobaa O, Staessen JA, BoggiA J: Blood pressure in relation to 24-hour urinary sodium and potassium excretion in a Uruguyan population sample. International Journal of Hypertension 2018, 2018:6956678.
14. van der Stouwe JG, Carmeli C, Aeschbacher S, Schoen T, Krissap I, Wenger G, Ehret G, Ponee B, Pruiman M, Ackermann D et al: Association of 24-hour blood pressure with urinary sodium excretion in healthy adults. Am J Hypertens 2018, 31(7):784-791.
15. Bankir L, Bochud M, Maillard M, Bovet P, Gabriel A, Burnier M: Nighttime blood pressure and nocturnal dipping are associated with daytime urinary sodium excretion in African subjects. Hypertension 2008, 51(4):891-898.
16. Fukuda M, Munemura M, Usami T, Nakao N, Takeuchi O, Kamiya Y, Yoshida A, Kimura G: Nocturnal blood pressure is elevated with natriuresis and proteinuria as renal function deteriorates in nephropathy. Kidney Int 2004, 65(2):621-625.
17. Kimura G, Dohi Y, Fukuda M: Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovascular events. Hypertension Research 2010, 33(6):515-520.
18. Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group M: Evaluation and management. Renal disease: synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Annals of Internal Medicine 2013, 158(11):825-830.
19. Wang C, Deng WJ, Gong WY, Zhang J, Zhang QZ, Ye ZC, Lou TQ: Nocturnal hypertension correlates better with target organ damage in patients with chronic kidney disease than a nondipping pattern. J Clin Hypertens 2015, 17(10):792-801.
20. Wang C, Deng WJ, Gong WY, Zhang J, Tang H, Peng H, Zhang QZ, Ye ZC, Lou TQ: High prevalence of isolated nocturnal hypertension in Chinese patients with chronic kidney disease. J Am Heart Assoc 2015, 4(6).
21. Wang C, Zhang J, Liu X, Li CC, Ye ZC, Peng H, Chen ZJ, Lou TQ: Reversed dipper blood-pressure pattern is closely related to severe renal and cardiovascular damage in patients with chronic kidney disease. PLoS One 2013, 8(2).
22. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS, Investigators C: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001, 12(12):2768-2774.

23. Glassock RJ, Pecoits R, Barberato SH: Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 2009, 4:579-591.

24. Levey AS, Stevens LA, Schmid CH, Zhang YP, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T et al: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150(9):604-612.

25. Assoc AD: Diagnosis and classification of diabetes mellitus. Diabetes Care 2012, 35(1):S64-S71.

26. Simon A, Megnien JL, Chironi G: The value of carotid intima-media thickness for predicting cardiovascular risk. Arterioscl Throm Vas 2010, 30(2):182-185.

27. Smyth A, O’Donnell MJ, Yusuf S, Clase CM, Teo KK, Canavan M, Reddan DN, Mann JFE: Sodium intake and renal outcomes: A systematic review. Am J Hypertens 2014, 27(10):1277-1284.

28. Kieneker LM, Eisenga MF, Gansevoort RT, de Boer RA, Navis G, Dullaart RPF, Joosten MM, Bakker SJL: Association of low urinary sodium excretion with increased risk of stroke. Mayo Clin Proc 2018, 93(12):1803-1809.

29. O’Donnell M: Urinary sodium and potassium excretion, mortality, and cardiovascular events (vol 371, pg 612, 2014). New Engl J Med 2014, 371(13):1267-1267.